PerpEquities

Equity · Healthcare

Thermo Fisher Scientific (TMO) perpetual futures

TMO perpetual futures on 3 crypto exchanges – live perp price vs the stock, funding rate, open interest and where to trade TMOUSDT.

Thermo Fisher Scientific is a global leader in scientific services, offering life sciences solutions, analytical instruments, diagnostics, and lab supplies to research and healthcare sectors.

$707.84+1.1%NYSE closed
Open in terminal

Price chart

 

Use the left and right arrow keys to inspect points on the chart.

Collecting venue price data...
venue perp mark · Ourbit (TMO/USDT)
Auto: highest-volume live perp venueOpen in TradingView

Trading data

Perpetual market activity

3/4 live markets
Venues
4
Live markets
3/4
24h volume
$108.5KCoverage: 2/3 marketsExchange-reported volume: $3.6M
Open interest
$378.1K
Best liquidity
$3.8K
MEXC
Tightest spread
+115.0 bps
MEXC
Highest volume
$107.2K
MEXC
Settlement mix
USDT · 4/4
Perp/spot vol.
0.00x
Spot volume $1.1B
OI / float
0.00%
Float $261.6B
Spot performance
1D+0.78%
5D-0.97%
1M+7.49%
6M+52.14%
YTD+21.46%
1Y+24.52%

Venue matrix

4 markets

Some venue links are sponsored. We may receive a commission, and eligible users may occasionally receive trading-fee discounts, at no additional cost to you.

Trade
MEXCTradeTMO/USDTTrading$707.84+14.8% APR
+0.014% every 8h
+115.0 bps$3.8K$107.2K$214.3KUSDT20x
Gate.ioTradeTMO/USDTTrading$706.700.0% APR
0.000% every 8h
+165.5 bps-$1.2K$5.5KUSDT20x
BingXTradeTMO-USDTWatchlist------USDT-
OurbitTradeTMO/USDTTrading$706.690.0% APR
0.000% every 8h
+165.5 bps$2.9K$3.5M⚠$158.3KUSDT20x

Unverified volume: implausibly high against open interest, a typical sign of wash trading. These venues are listed last.

Tradability

Execution quality

Entry cost and depth per venue at $1k–$100k

No sufficient depth · 0 of 3 venues absorb $10k

No fresh book data: MEXC, Ourbit, Gate.io

Taker execution estimate incl. approx. fees - maker fills are not guaranteed.

Best venues for this underlying

Best liquidity

TMO

Tightest spread

TMO

Highest volume

TMO

Funding history

Stored venue snapshots by market

Company financials

Financials at a glance

Last report Q3 '26 · filed 2026-10-30 · next report 2027-02-04 · Updated 4h ago
All financials →

Valuation & key figures

Market cap
$261.6B
Updated 4h ago
Revenue
$47.4B
Trailing 12 months
Revenue growth
+8%
Next fiscal year
Profit margin
+15.0%
P/E
37.2
Peer P/E 29.6
P/S
5.5
Peer P/E
29.6
Similar listed perps
Free cash flow
$7.6B
Trailing 12 months
Net income
$7.1B
Trailing 12 months
Revenue estimate
$48B
Next fiscal year
Earnings
2027-02-04
Revenue est. $12.8B · Updated 4h ago
Dividend
$0.47
2026-09-15
Revenue (TTM)$47.4B+8.3% vs a year agoLast 4 quarters; bars = each quarter
Operating margin (TTM)18.0%-0.5 pp vs a year agoOperating income $8.52B
Net income (TTM)$7.08B+7.8% vs a year agoAfter tax, incl. non-operating gains
Free cash flow (TTM)$7.6B+24.3% vs a year agoCapex $1.73B
Diluted EPS (TTM)$18.96+9.5% vs a year agoSum of the last 4 quarters
Net cash-$35.3B-9.9% vs a year agoCash + short-term investments - debt
  • Last report (2026-10-21): revenue beat by 1.5%, EPS beat by 4.4%Revenue $12.1B vs $12B expected (+1.5%); EPS $6.68 vs $6.40 (+4.4%).
  • Revenue growth accelerating: 9.1% year on yearQ3 '26 revenue $12.1B, against an average of 7.2% over the four quarters before.
  • Operating margin 18.0% (TTM), -0.5 pp on a year agoOperating income grew 5.1% while revenue grew 8.3%.
  • Capex 3.6% of revenue (a year ago 3.5%)$1.73B invested in the last 4 quarters (+12.2% on a year earlier). Free cash flow $7.6B = 107.2% of net income.

Revenue, operating income and growth

quarterly

Segments in Q3 '26

from the filing
SegmentRevenuey/yOp. incomeMargin
Laboratory Products And Biopharma Services$6.82B+15.1%$1.07B15.6%
Life Sciences Solutions$2.28B+3.9%$1.02B44.8%
Analytical Instruments$1.95B+5.5%$538M27.6%
Specialty Diagnostics$1.09B-5.5%$341M31.3%
In the full financialsIncome statement, balance sheet and cash flow (12 quarters / 10 years) · margins and cost structure · capital allocation and buybacks · valuation against the 5-year range · analyst estimates · all 325 lines Thermo Fisher Scientific Inc. reported to the SEC

Next catalyst

Catalysts

Earnings
2027-02-04
Revenue est. $12.8B · Updated 4h ago
Dividend
$0.47
2026-09-15

No unusual perp activity right now.

Research data

Analysts, filings and peer context

Estimates

6
DateEPS estimateRevenue estimateGrowthAnalysts
FY 202625.29$48B+8%15
FY 202727.74$50.6B+13%16
FY 202830.63$53.8B+21%6
FY 202933.92$57.2B+28%3
FY 203037.24$59.2B+33%2
Q1 20276.06$11.7B+7%9

Company events

6
2027-02-04EarningsActual - / Estimate 7.13-
2026-10-21Earnings · Before market openActual 6.68 / Estimate 6.4Beat
2026-09-15Dividend$0.47-
2026-07-23EarningsActual 6.03 / Estimate 5.72Beat
2026-06-15Dividend$0.47-
2026-04-23EarningsActual 5.44 / Estimate 5.25Beat

Peer comparison

Similar listed perps

Company data

Company intelligence

Updated: Nov 4, 2026, 09:40 PM UTC

Company profile

Sector
Healthcare
Industry
Medical - Diagnostics & Research
Chief executive
Marc N. Casper
Employees
125,000
IPO date
Mar 17, 1980
Country
US
Exchange
New York Stock Exchange
Website
Altman Z-scorei4.18
Piotroski scorei7/9
Overall ratingiB
Owner earningsi$2.36B$6.35 per share
ESG risk ratingiBIndustry rank: 20 out of 62

Rating factors

Return on equityi
4
Return on assetsi
4
Debt to equityi
1
Price to earningsi
2
Price to booki
2
Market cap history
$258.39B+23.3%Aug 26 – Nov 26
$209.52B$233.95B$258.39BLow: $209.52B · 2026-08-04Latest: $258.39B · 2026-11-03Aug 26Sep 26Oct 26Nov 26
Latest: $258.39B · 2026-11-03High: $258.39B · 2026-11-03Low: $209.52B · 2026-08-04
Largest fund holders
FundWeightShares held
VTI0.34%11.7M
VECA.S0.15%10.2M
VOO0.38%9.7M
VCPA.S0.14%6.6M
IVV0.39%4.9M
1657.T0.3%4.9M
XAW.TO0.23%4.9M
XSP.TO0.39%4.9M
XWD.TO0.29%4.9M
FCNKX1.82%4.8M
FXAIX0.38%4.7M
SPY0.39%4.5M

Analyst track record

How the analysts covering TMO have done: ratings, price-target accuracy and the measured reaction after their calls.

12 months3 years
Ratings123362
Analysts3346
Buy / hold / sell106 / 17 / 0310 / 52 / 0
Upgrades / downgrades / initiations4 / 2 / 99 / 6 / 17
Price targets hit / missed84 / 27 (76%)303 / 32 (90%)
Avg. return after a rating (TipRanks)+8.6%+14.2%
Best / worst call+44.7% / -14.6%+57.6% / -14.6%

After buy calls on this stock: median 21-day move +2.0% vs S&P 500 -0.5% (n = 314)

Most accurate on this stock

Share of an analyst's price targets on this stock that the price reached within 12 months (our measurement over the last 3 years, at least 8 targets). It describes past calls, not the odds of the current one.

  1. Vijay KumarEvercore ISI91% hit rate on this stock · 11 targets measuredBuytarget $570Jul 6, 2026
  2. Catherine Ramsey SchulteRobert W. Baird69% hit rate on this stock · 13 targets measuredBuytarget $756Oct 22, 2026
  3. Michael RyskinBank of America Securities68% hit rate on this stock · 19 targets measuredBuytarget $795Oct 22, 2026

Latest ratings

DateAnalystCallTarget
Nov 2, 2026Luke SergottBarclaysBuyMaintained$775
Nov 2, 2026Unknown AnalystGuggenheimBuyReiterated$740
Oct 29, 2026David ToungArgus ResearchBuyReiterated$780
Oct 30, 2026‏Avantika Dhabaria‏Bank of America SecuritiesBuyMaintained$795
Oct 30, 2026‏Avantika Dhabaria‏Bank of America SecuritiesBuyMaintained$795
Consensus over the last 12 months buy hold sell avg. target month-end close
Monthly buy, hold and sell shares of analyst ratings with the average price target and the month-end close$500$550$600$650$700Dec 25 · Buy 25 · Hold 1 · Sell 0Dec 25Jan 26 · Buy 23 · Hold 1 · Sell 0Feb 26 · Buy 23 · Hold 1 · Sell 0Feb 26Mar 26 · Buy 21 · Hold 1 · Sell 0Apr 26 · Buy 18 · Hold 2 · Sell 0Apr 26May 26 · Buy 20 · Hold 2 · Sell 0Jun 26 · Buy 18 · Hold 5 · Sell 0Jun 26Jul 26 · Buy 20 · Hold 5 · Sell 0Aug 26 · Buy 20 · Hold 5 · Sell 0Aug 26Sep 26 · Buy 24 · Hold 5 · Sell 0Oct 26 · Buy 23 · Hold 6 · Sell 0Oct 26Nov 26 · Buy 23 · Hold 6 · Sell 0Dec 25 · avg. target $629Jan 26 · avg. target $649Feb 26 · avg. target $652Mar 26 · avg. target $658Apr 26 · avg. target $631May 26 · avg. target $620Jun 26 · avg. target $589Jul 26 · avg. target $613Aug 26 · avg. target $615Sep 26 · avg. target $640Oct 26 · avg. target $709Nov 26 · avg. target $709Dec 25 · month-end close $579Jan 26 · month-end close $579Feb 26 · month-end close $521Mar 26 · month-end close $492Apr 26 · month-end close $479May 26 · month-end close $493Jun 26 · month-end close $501Jul 26 · month-end close $574Aug 26 · month-end close $617Sep 26 · month-end close $675Oct 26 · month-end close $697Nov 26 · month-end close $697

Share of analysts per call each month (latest call per analyst within 180 days). Targets and closes in USD.

TipRanks data · computed Nov 2, 2026 · 123 ratings

Frequently asked questions

Where can I trade TMO perpetual futures?

Thermo Fisher Scientific (TMO) perpetual futures trade on 3 crypto venues, including Ourbit, MEXC, Gate.io. PerpEquities compares them by live price, funding rate, open interest and liquidity.

Can I trade TMO around the clock?

Yes. Unlike the underlying stock, TMO perpetuals trade 24/7 — including weekends and outside regular market hours.

What is the funding rate on TMO perpetuals?

Right now the TMO perp funding rate is 0.0% annualized (venue median), ranging from 0.0% to +14.8% across 3 venues. A positive rate means longs pay shorts. PerpEquities shows the live rate and its history for every venue.

How does the TMO perp price compare to the Thermo Fisher Scientific stock?

The venue-median TMO perp mark is $706.7 versus a reference stock price of $707.8, a basis of -0.2%. Perps follow the stock through an index price; the gap widens when funding or liquidity diverge between venues.

What is a TMO perpetual future?

A TMO perpetual is a derivative that tracks the price of Thermo Fisher Scientific with no expiry date. It lets you take long or short exposure to Thermo Fisher Scientific on crypto venues, around the clock.

What is TMOUSDT perpetual?

TMOUSDT is the symbol most crypto exchanges use for the Thermo Fisher Scientific perpetual settled in USDT (Tether). It tracks the TMO share price through an index, trades 24/7 with leverage and never expires.

Embed this asset

TMO perpetuals · perpequities.comTMO perpetuals · perpequities.com
<a href="https://perpequities.com/stocks/tmo-perp"><img src="https://perpequities.com/badge/tmo-perp.svg" width="240" height="64" alt="TMO perpetuals · perpequities.com" loading="lazy"></a>

Next step

Stay on top of TMO perps

Signals with a track record

Analysts who hit 70%+ of their targets on the perps we track, congress buys over $500k, 13F positions over $5M, funding spreads that have paid for days. Every post shows the evidence. Free, no sign-up.

Join on Telegram

Weekly digest by email

The listings, funding and moves that matter for TMO — one email every Sunday.

Watchlist and alerts

Price and funding alerts for TMO, via push or Telegram.

Set an alert

Follow the live feed

Daily movers, new listings and funding extremes as they happen.

Follow on X